Haemonetics Corporation  

(Public, NYSE:HAE)   Watch this stock  
Find more results for HAE
-0.79 (-1.75%)
Feb 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 44.41 - 45.42
52 week 29.86 - 45.42
Open 45.08
Vol / Avg. 0.00/282,856.00
Mkt cap 2.29B
P/E 77.02
Div/yield     -
EPS 0.58
Shares 51.49M
Beta 0.71
Inst. own 106%
Apr 27, 2015
Q4 2015 Haemonetics Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 3, 2015
Haemonetics Corp at Raymond James Institutional Investors Conference - 2:50PM EST - Add to calendar
Jan 29, 2015
Q3 2015 Haemonetics Corp Earnings Call - Webcast
Jan 29, 2015
Q3 2015 Haemonetics Corp Earnings Release
Jan 13, 2015
Haemonetics Corp at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 6.90% 3.75%
Operating margin 7.88% 5.04%
EBITD margin - 13.93%
Return on average assets 4.35% 2.36%
Return on average equity 7.75% 4.37%
Employees 3,782 -
CDP Score - -


United States - Map
+1-781-8487100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Haemonetics is a healthcare company dedicated to providing blood management solutions to customers. The Company�s portfolio of integrated devices, information management, and consulting services offers blood management solutions. The Company serves in three markets, such as manufacturers of plasma derived pharmaceuticals, blood collectors, and hospitals. The Company�s product categories include: Plasma, Blood Center, Hospital, and Software Solutions. Human plasma is collected and processed by bio-pharmaceutical companies into therapeutic and diagnostic products. The blood donations produce blood products for transfusion to surgical, trauma, or chronically ill patients. Loss of blood is common in many surgical procedures, including open heart, trauma, transplant, vascular, and orthopedic procedures, and the need for transfusion of oxygen-carrying red cells to make up for lost blood volume. The Company has a suite of software solutions for helping ensure donor and patient safety.

Officers and directors

Brian P. Concannon President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Christopher J. Lindop Chief Financial Officer, Executive Vice President - Business Development
Age: 56
Bio & Compensation  - Reuters
Peter M. Allen President - Global Plasma
Age: 55
Bio & Compensation  - Reuters
David D. Helsel Executive Vice President - Global Manufacturing
Age: 50
Bio & Compensation  - Reuters
Jonathan White Chief Science and Technology Officer
Age: 54
Bio & Compensation  - Reuters
Susan Hanlon Chief Accounting Officer, Vice President - Finance
Age: 46
Bio & Compensation  - Reuters
Sandra Jesse Vice President, Chief Legal Officer
Age: 61
Bio & Compensation  - Reuters
Richard J. Meelia Non-Executive Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Susan Bartlett Foote Independent Director
Age: 67
Bio & Compensation  - Reuters
Ronald G. Gelbman Independent Director
Age: 66
Bio & Compensation  - Reuters